| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 21.93▼ | 22.09▼ | 22.13▼ | 22.14▼ | 22.82▼ |
| MA10 | 21.98▼ | 22.29▼ | 22.43▼ | 22.86▼ | 22.71▼ |
| MA20 | 22.08▼ | 22.53▼ | 22.32▼ | 23.64▼ | 22.32▼ |
| MA50 | 22.31▼ | 22.28▼ | 22.50▼ | 23.01▼ | 21.10▲ |
| MA100 | 22.53▼ | 22.64▼ | 23.52▼ | 22.13▼ | 22.46▼ |
| MA200 | 22.28▼ | 23.62▼ | 23.52▼ | 21.17▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.016▼ | -0.108▼ | -0.055▼ | -0.305▼ | -0.004▼ |
| RSI | 25.532▼ | 36.812▼ | 37.774▼ | 41.930▼ | 49.585▼ |
| STOCH | 14.915▼ | 5.212▼ | 4.263▼ | 18.186▼ | 48.364 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -87.608▼ | -60.033 |
| CCI | -150.660▼ | -140.519▼ | -183.743▼ | -78.663 | -28.141 |
| MA | $AVBP Price Crossed Below MA(7) | Set Alert |
|
Tuesday, March 24, 2026 11:00 PM
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) will present preclinical data on two cancer drug candidates at the American Association for Cancer Research Annual Meeting 2026 in San ...
|
|
Tuesday, March 24, 2026 04:02 AM
The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and potentially longer progression-free survival compared with the current standard of care. If the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/03/26 | 22.41 | 23.33 | 21.77 | 21.805 | 229,733 |
| 25/03/26 | 22.34 | 22.98 | 22.34 | 22.75 | 239,747 |
| 24/03/26 | 21.91 | 22.08 | 21.09 | 21.95 | 384,526 |
| 23/03/26 | 22.34 | 22.72 | 21.73 | 22.18 | 494,497 |
| 20/03/26 | 22.80 | 23.10 | 21.94 | 22.02 | 1,300,424 |
| 19/03/26 | 22.81 | 23.20 | 22.22 | 22.86 | 339,606 |
| 18/03/26 | 24.75 | 24.75 | 22.625 | 22.81 | 489,529 |
| 17/03/26 | 24.26 | 24.66 | 23.90 | 24.01 | 298,406 |
| 16/03/26 | 24.37 | 24.93 | 24.01 | 24.31 | 254,330 |
| 13/03/26 | 24.27 | 25.00 | 23.70 | 23.90 | 264,098 |
|
|
||||
|
|
||||
|
|